[go: up one dir, main page]

DK1163008T3 - Use of trehalose to stabilize a liquid vaccine - Google Patents

Use of trehalose to stabilize a liquid vaccine

Info

Publication number
DK1163008T3
DK1163008T3 DK00912734T DK00912734T DK1163008T3 DK 1163008 T3 DK1163008 T3 DK 1163008T3 DK 00912734 T DK00912734 T DK 00912734T DK 00912734 T DK00912734 T DK 00912734T DK 1163008 T3 DK1163008 T3 DK 1163008T3
Authority
DK
Denmark
Prior art keywords
trehalose
liquid vaccine
stabilize
vaccine composition
liquid
Prior art date
Application number
DK00912734T
Other languages
Danish (da)
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK1163008T3 publication Critical patent/DK1163008T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention concerns a liquid vaccine composition comprising at least an antigen consisting of a polysaccharide bound to a carrier protein and trehalose. The invention also concerns a method for stabilising a liquid vaccine composition which consists in adding trehalose to the vaccine composition.
DK00912734T 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine DK1163008T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (en) 1999-03-23 1999-03-23 USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
PCT/FR2000/000730 WO2000056365A1 (en) 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine

Publications (1)

Publication Number Publication Date
DK1163008T3 true DK1163008T3 (en) 2003-11-17

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912734T DK1163008T3 (en) 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine

Country Status (11)

Country Link
EP (1) EP1163008B1 (en)
JP (1) JP2002540079A (en)
AT (1) ATE246937T1 (en)
AU (1) AU3438900A (en)
CA (1) CA2366869A1 (en)
DE (1) DE60004496T2 (en)
DK (1) DK1163008T3 (en)
ES (1) ES2200845T3 (en)
FR (1) FR2791895B1 (en)
PT (1) PT1163008E (en)
WO (1) WO2000056365A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
SI2351579T1 (en) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
AU2004277758A1 (en) 2003-10-02 2005-04-14 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
CN101489587B (en) * 2006-05-12 2015-05-27 伯哈拉特生物技术国际有限公司 A composition useful as a vaccine
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
EA201490303A1 (en) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. VACCINE
KR20160005378A (en) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
MX338753B (en) 2009-09-30 2016-04-29 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides.
CN102869377A (en) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 Immunogenic composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
CN102793919A (en) 2011-05-20 2012-11-28 日东电工株式会社 Pharmaceutical composition and method for producing the same
TR201909110T4 (en) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates.
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
JP2015518845A (en) 2012-05-22 2015-07-06 ノバルティス アーゲー Neisseria meningitidis serogroup X conjugate
FR2992656B1 (en) * 2012-07-02 2016-10-07 Sanofi Pasteur METHOD FOR PRODUCING ANTIGENS HAEMOPHILUS INFLUENZAE TYPE B
CN104487086B (en) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 Non-animal derived nonalcoholic vaccine composition and preparation method thereof
RU2015106791A (en) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са IMMUNOGENIC COMPOSITIONS
WO2014100853A1 (en) * 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11149255B2 (en) 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
CA3054866A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Personalised immunogenic peptide identification platform
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
JP7642530B2 (en) 2018-09-04 2025-03-10 トレオス バイオ リミテッド Peptide Vaccine
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CN115715199A (en) 2020-04-03 2023-02-24 帕普泰克疫苗有限公司 Coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (en) * 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
DE69419966T2 (en) * 1993-05-17 2000-01-20 Akzo Nobel N.V., Arnheim/Arnhem Vaccine against Streptococcus suis infection
JP4142095B2 (en) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド Method for preventing aggregation of various substances during rehydration or melting, and composition obtained by the method
JP4653262B2 (en) * 1996-09-26 2011-03-16 メルク・シャープ・エンド・ドーム・コーポレイション Rotavirus vaccine preparations
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
FR2791895B1 (en) 2001-06-15
EP1163008B1 (en) 2003-08-13
CA2366869A1 (en) 2000-09-28
WO2000056365A1 (en) 2000-09-28
PT1163008E (en) 2003-12-31
FR2791895A1 (en) 2000-10-13
DE60004496D1 (en) 2003-09-18
JP2002540079A (en) 2002-11-26
ATE246937T1 (en) 2003-08-15
DE60004496T2 (en) 2004-04-08
AU3438900A (en) 2000-10-09
ES2200845T3 (en) 2004-03-16
EP1163008A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
DK1163008T3 (en) Use of trehalose to stabilize a liquid vaccine
BR0114646A (en) humanized anti-lt-beta-r antibodies
CY2019029I1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
CY1112687T1 (en) METHOD FOR USING DICTIONARIES AND COMPOSITIONS THAT INCLUDE
ID26033A (en) METHOD OF STABILIZATION OF PHARMACEUTICAL COMPOSITION MATERIALS WITH SPECIFIC USE OF ANTIOXIDE
DE50202328D1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANE
DE60144145D1 (en) Subtilisin variant
DK1914244T3 (en) Method for modulating the activity of functional immune molecules.
ATE223702T1 (en) METHOD AND COMPOSITIONS FOR MICROCAPSULATING ADJUVANTS
DE60007095T2 (en) CALANOLIDE FOR INHIBITING BTK
DE60125797D1 (en) IMPFSTOFFZUSAMMESETZUNG
FI20012281A0 (en) Method and system for generating personalized messages
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
NO20031860L (en) Kahalalid F
DK1235579T3 (en) Pharmaceuticals containing trimegestone
DE69836976D1 (en) NEOSPORA IMPSTOFF
DE69840637D1 (en) COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINES USING CHEMOKINS
DE60222296D1 (en) VACCINATED VIRUS AND METHOD FOR THE PRODUCTION THEREOF
MXPA03002875A (en) VACCINE COMPOSITION AND STABILIZATION METHOD.
ATE295182T1 (en) COMPOSITIONS FOR IMMUNO-BOOSTING VACCINES
DE10292736D2 (en) Flooring
ATE255594T1 (en) HEPATITIS B INHIBITORS
DK1159426T3 (en) Cloning and expression of Haemophilus somnus transferrin-binding proteins